December 29, 2016 / 5:26 PM / a year ago

BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, gold stocks, Cempra

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, here ; for the Morning News Call newsletter, here )

U.S. stocks gave up early gains and were little changed in light trading on Thursday as a weakness in financial stocks offset gains in healthcare companies.

The Dow Jones Industrial Average was down 0.18 percent at 19,798.92, the S&P 500 was down 0.16 percent at 2,246.21 and the Nasdaq Composite was down 0.32 percent at 5,421.294.

** NVIDIA CORP, $106.03, -2.95 pct

** ADVANCED MICRO DEVICES INC, $11.325, -1.95 pct

Nvidia’s stock was on track for the second straight day of losses after short seller Citron Research tweeted that the chipmaker’s shares would slip to $90 in 2017.

Rival Advanced Micro Devices also fell on the news.

** GOLDCORP INC, $13.73, +4.33 pct

** NEWMONT MINING CORP, $34.59, +5.52 pct

** ALAMOS GOLD INC, $7.27, +10.82 pct

** IAMGOLD CORP, $3.9, +6.56 pct

** YAMANA GOLD INC, $2.96, +8.03 pct

** AGNICO EAGLE MINES LTD, $42.74, +5.53 pct


** GOLD FIELDS LTD, $3.16, +5.33 pct

Gold prices rose to their highest in two weeks on Thursday, helped by a decline in dollar and U.S. bond yields following weaker-than-expected economic data.

** CEMPRA INC, $2.675, -56.15 pct

The drug developer said the U.S. FDA rejected its antibiotic to treat pneumonia, citing inadequate data on the drug’s impact on the liver and unresolved manufacturing issues.

** SEARS HOLDINGS CORP, $8.335, +1.89 pct

The company said it obtained a secured standby letter of credit facility of up to $200 million from ESL Investments Inc, the hedge fund headed by Sears CEO Edward Lampert, that would help the company with additional liquidity to fund its operations.

** FORTRESS BIOTECH INC, $2.78, +21.40 pct

The drug developer said a case study from an early-stage trial of its treatment for glioblastoma, a type of brain tumor, would be published in a medical journal on Thursday.

** PRIMA BIOMED LTD, $2.49, +6.99 pct

The Australian biotechnology company said interim data from trial showed its drug, IMP321, in combination with PD-1 blocking antibody, is safe to treat patients with metastatic melanoma, a type of skin cancer.


The molecular diagnostic test and pathology service provider implemented 1-for-10 reverse stock split, bringing its outstanding shares down to 2 million from 20.2 million. (Compiled by Komal Khettry in Bengaluru; Editing by Anil D’Silva)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below